Compare Cassava Sciences Inc (FLNA) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Orion Office REIT Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Orion Office REIT Inc trades at $2.69 (market cap $151.17M). The key difference: Orion Office REIT Inc is far larger — about 2.8× Cassava Sciences Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | ONL | |
|---|---|---|
Market Cap | $53.14M | $151.17M |
Sector | Health | Real Estate |
52-Week High | $4.64 | $3.04 |
52-Week Low | $1.09 | $1.93 |
Enterprise Value | -$33.43M | $634.82M |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
ONL trades at $2.695, up 1.32% with a bearish technical signal. The REIT shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, with a -98.36% net margin. However, positive cash flow from operations and a strategic review with Wells Fargo and JPMorgan provide some optimism. Analyst sentiment is split evenly between Buy and Hold recommendations.
The outlook is challenged by fundamental weakness but supported by balance sheet management efforts. Investment opportunity lies in the potential outcome of the strategic review and portfolio repositioning. Key risks include continued revenue erosion, high debt levels, and negative funds from distribution amid significant capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
